Pediatric acute myeloid leukemia: towards high-quality cure of all patients.
about
Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemiaPanobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51Prospective evaluation of whole genome microRNA expression profiling in childhood acute lymphoblastic leukemia.Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells.Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study.Effective non-viral delivery of siRNA to acute myeloid leukemia cells with lipid-substituted polyethyleniminesEvaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemiaEngagement of SIRPĪ± inhibits growth and induces programmed cell death in acute myeloid leukemia cells.Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage.Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemiaValproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells.JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors.Anti-cancer effects of ginsenoside compound k on pediatric acute myeloid leukemia cells.Recurrent deletions of IKZF1 in pediatric acute myeloid leukemiaDevelopment of treatment and clinical results in childhood acute myeloid leukemia in Poland.Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML).Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors.Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: a retrospective, international study.The role of HDACs inhibitors in childhood and adolescence acute leukemias.The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia.Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.Pediatric acute myeloid leukemia.Novel insights into etiologies of leukemia: a HuGE review and meta-analysis of CYP1A1 polymorphisms and leukemia risk.A critical review of which children with acute myeloid leukaemia need stem cell procedures.How I treat paediatric relapsed acute myeloid leukaemia.Corneal Epithelial Microcysts due to High-Dose Cytarabine Administration in a Pediatric Acute Myeloid Leukemia Patient.Targeting SLUG sensitizes leukemia cells to ADR-induced apoptosis.Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia.Relapsed acute myeloblastic leukemia: first pediatric randomized study.Recurrent translocation t(10;17)(p15;q21) in minimally differentiated acute myeloid leukemia results in ZMYND11/MBTD1 fusion.Outcomes of allogeneic stem cell transplantation among patients with acute myeloid leukemia presenting active disease: Experience of a single European Comprehensive Cancer Center.Outcome of children with acute myeloid leukaemia (AML) experiencing primary induction failure in the AIEOP AML 2002/01 clinical trial.Family History and Relapse in Pediatric Acute Myeloid Leukemia.Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target.The kinetics of relapse in DEK-NUP214-positive acute myeloid leukemia patients.Inhibition of ERK5 enhances cytarabine-induced apoptosis in acute myeloid leukemia cells.Outcome of childhood acute promyelocytic leukemia treated using a modified AIDA protocol.BCOR and BCORL1 mutations in pediatric acute myeloid leukemia.
P2860
Q28385690-D7D46230-5470-48BD-8B3C-5CEDD5E42821Q28535006-AE425026-7BDC-4190-9F30-F4B8A1AD162DQ33740014-06C713BC-32CC-4A5D-BF5C-D159034C1E6FQ33831971-71F59562-BA1A-4D66-8CC8-2B9DA529DEB3Q34080807-B0E1FE0D-3440-4162-84DA-3636B1719902Q34406423-A3A02D5C-B9C5-466D-A47B-7CC4F91FC00EQ34542996-AA574ECD-4CE2-490B-B65D-77B9A4C28444Q34548156-6C6CD3D4-89EB-4B0F-9C5C-53774B051BBBQ34612599-A038C6D4-C3D2-4B19-8610-B97B7F6CF6FAQ35007971-9DD615BB-FFDA-4D5D-9B43-41C8A51C0683Q35265916-387FB5D1-3B32-412A-B45B-2A0454A6B4A6Q36094977-91CD951E-E510-49C8-87E2-44E9F3B1C6BFQ36199628-E8464494-2751-43D1-9E43-404625E61016Q36697954-F6780C20-B3FA-49CC-9B0B-ED83D952D9E6Q36709009-587E28A0-1088-4766-B43F-41EA9928FD45Q36736376-3D1840BF-F7F4-42D1-B24A-EEBA484E1462Q36739522-D92AF600-E772-4E76-92A4-8A74D9DDF0E5Q37325012-41B8704F-E707-4AFE-9FF8-F58330D11C39Q37552027-26EF5D64-6BE3-4CEC-8EA0-76D0254B61A6Q37841146-E03C6EF8-4B7E-4276-B792-DEAED7278959Q37874929-4209783E-3DDE-434B-92E6-A74570A783CBQ37934964-0E6EE7A5-DE19-40ED-AD83-09F4DB6EFA93Q37988570-41D617BE-C76C-444B-AE75-FEF1BFE5E7F0Q38109462-2152296B-3BE9-4263-ABE2-5B3E6027611DQ38205864-C3ABBC14-295B-4908-A6DB-1A294DAD13D0Q38212509-C32010E6-12F2-42F4-9DC5-11088E526A7DQ38754351-18657E3A-A227-461A-92CF-EAF8F9109411Q38793536-BFE48223-A7F4-4D26-B426-5A182816C50FQ39401851-AD281CC0-2F46-495A-87A0-6EFBAFC85781Q40033160-90E8F9AD-8EA4-4E3F-BF13-E3A3FA265A02Q40273592-E5E60351-4934-4167-BAEA-14048F5F5E0DQ40438036-7F2DD52D-162A-4FC0-B065-C40F1BE24663Q40681571-E631F032-04EA-48BA-858D-8EBF7F7C740DQ40726025-C4AA65F5-A745-4DD6-81B4-02F5D350D58DQ41009977-FDCDC4E4-59B6-4F33-9D22-1B351D97446DQ41368368-FF3943C0-A98D-421C-AC87-1ED445AF4820Q41553306-108BB192-7F49-46BF-8322-653BF42FCAF3Q41643520-5A9B8730-69B7-49C9-B148-D64358F98097Q42284173-738BB30A-4C0C-49C1-8384-4F0CC82E6EDCQ42573846-34EA10F8-D73B-4409-B475-952D46B31593
P2860
Pediatric acute myeloid leukemia: towards high-quality cure of all patients.
description
2007 nĆ® lÅ«n-bĆ»n
@nan
2007幓ć®č«ę
@ja
2007幓å¦ęÆęē«
@wuu
2007幓å¦ęÆęē«
@zh-cn
2007幓å¦ęÆęē«
@zh-hans
2007幓å¦ęÆęē«
@zh-my
2007幓å¦ęÆęē«
@zh-sg
2007幓åøč”ęē«
@yue
2007幓åøč”ęē«
@zh
2007幓åøč”ęē«
@zh-hant
name
Pediatric acute myeloid leukemia: towards high-quality cure of all patients.
@en
Pediatric acute myeloid leukemia: towards high-quality cure of all patients.
@nl
type
label
Pediatric acute myeloid leukemia: towards high-quality cure of all patients.
@en
Pediatric acute myeloid leukemia: towards high-quality cure of all patients.
@nl
prefLabel
Pediatric acute myeloid leukemia: towards high-quality cure of all patients.
@en
Pediatric acute myeloid leukemia: towards high-quality cure of all patients.
@nl
P356
P1433
P1476
Pediatric acute myeloid leukemia: towards high-quality cure of all patients.
@en
P2093
Christian M Zwaan
Gertjan J L Kaspers
P304
P356
10.3324/HAEMATOL.11203
P577
2007-11-01T00:00:00Z